Option chain shows key data for Chugai Pharmaceutical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Chugai Pharmaceutical.

Chugai Pharmaceutical (OTC:CHGCF) Stock, Option Chain

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ABBV

ABOS

ALXO

ANVS

ARGNF

CHGCF

HALO

RHHBY

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company&#39;s proprietary ENHANZE manufacturing methods.

Halozyme&#39;s ENHANZE Product Gets New Patent Grant in EU

CHUGAI PHARMACEUTICAL by Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co Ltd

Harding Loevner International Equity Q2 2024 Report

Harding Loevner International Equity ADR Q2 2024 Report

Harding Loevner International Developed Markets Equity Q2 2024 Report

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co. has increased its full-year revenue and profit forecasts for 2...

Chugai Pharmaceutical Boosts 2024 Revenue Forecast

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co. has announced an upward revision in its financial forecasts fo...

Chugai Pharmaceuticals Revises Financial Forecasts

Chugai Pharmaceutical Co (JP:4519) has released an update. Chugai Pharmaceutical Co. has reported a strong financial performance for the first nine...

Chugai Pharmaceutical Reports Strong Financial Growth in 2024

Chugai Pharmaceutical reports 9M results

Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript

Harding Loevner International Equity ADR Q3 2024 Report

AAGIY

AAIGF

AAUKF

ADYEY

ADYYF

ALIZF

ALIZY

ASAZF

ASAZY

ASML

ASMLF

BBVA

BBVXF

BHPLF

BNDSF

BNDSY

BNTX

CHGCY

CLPBF

CLPBY

COCSF

DASTF

DASTY

DBSDF

DBSDY

GBOOF

GBOOY

GMAB

GNMSF

HLNCF

HRSHF

HSHCY

IFNNF

IFNNY

LRLCF

LRLCY

MELI

NGLOY

NONOF

NSRGF

NSRGY

NVDA

NVZMF

NVZMY

PIAIF

PNGAY

QIHCF

RHHBF

RHHVF

SAPGF

SBGSF

SBGSY

SGIOF

SGIOY

SHMDF

SMNNY

SNEJF

SONVF

SONVY

SONY

SSMXF

SSMXY

TCEHY

TCTZF

TSMWF

XNGSF

XNGSY

Chugai Pharmaceutical

Comments

Chugai Pharmaceutical

Chugai Pharmaceutical (CHGCF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga